Several other analysts have also issued reports on GKOS. Bank of America lowered shares of Glaukos from a buy rating to an underperform rating and set a $67.00 price target on the stock. in a research report on Monday, September 30th. Zacks Investment Research upgraded shares of Glaukos from a sell rating to a hold rating and set a $76.00 price target on the stock in a research report on Thursday, September 12th. BTIG Research restated a hold rating on shares of Glaukos in a research report on Wednesday, October 30th. Finally, JPMorgan Chase & Co. set a $90.00 target price on shares of Glaukos and gave the company a buy rating in a research report on Thursday, October 10th. One analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $74.75.
NYSE GKOS opened at $62.69 on Friday. The company has a current ratio of 6.32, a quick ratio of 5.94 and a debt-to-equity ratio of 0.42. The firm has a market capitalization of $2.31 billion, a price-to-earnings ratio of -169.43 and a beta of 1.66. The firm’s 50 day simple moving average is $63.45 and its 200 day simple moving average is $67.92. Glaukos has a 1 year low of $50.60 and a 1 year high of $84.65.
Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, November 6th. The medical instruments supplier reported ($0.10) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.17) by $0.07. The business had revenue of $58.51 million for the quarter, compared to analyst estimates of $56.96 million. Glaukos had a negative net margin of 8.60% and a negative return on equity of 4.01%. The firm’s revenue for the quarter was up 33.2% on a year-over-year basis. During the same quarter last year, the business posted ($0.17) EPS. On average, equities research analysts forecast that Glaukos will post -0.35 earnings per share for the current year.
In other Glaukos news, CFO Joseph E. Gilliam sold 3,750 shares of the firm’s stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $68.50, for a total value of $256,875.00. The sale was disclosed in a document filed with the SEC, which is available at this link. Insiders sold 10,881 shares of company stock worth $716,702 in the last 90 days. Company insiders own 8.70% of the company’s stock.
A number of institutional investors have recently modified their holdings of the business. Baillie Gifford & Co. raised its stake in shares of Glaukos by 60.6% during the second quarter. Baillie Gifford & Co. now owns 2,825,084 shares of the medical instruments supplier’s stock valued at $213,012,000 after acquiring an additional 1,065,462 shares during the last quarter. Nuveen Asset Management LLC bought a new position in shares of Glaukos during the second quarter valued at $15,603,000. C WorldWide Group Holding A S raised its stake in shares of Glaukos by 372.8% during the second quarter. C WorldWide Group Holding A S now owns 209,265 shares of the medical instruments supplier’s stock valued at $15,779,000 after acquiring an additional 165,000 shares during the last quarter. Brown Capital Management LLC raised its stake in shares of Glaukos by 6.1% during the second quarter. Brown Capital Management LLC now owns 2,618,462 shares of the medical instruments supplier’s stock valued at $197,432,000 after acquiring an additional 150,931 shares during the last quarter. Finally, Point72 Asset Management L.P. raised its stake in shares of Glaukos by 524.4% during the second quarter. Point72 Asset Management L.P. now owns 149,354 shares of the medical instruments supplier’s stock valued at $11,261,000 after acquiring an additional 125,436 shares during the last quarter.
Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery.
Further Reading: How Do Mutual Funds Work?
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.